Mustang Bio (MBIO)
(Delayed Data from NSDQ)
$0.28 USD
-0.01 (-4.83%)
Updated Sep 10, 2024 03:59 PM ET
After-Market: $0.28 0.00 (0.07%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth D Momentum C VGM
Brokerage Reports
Mustang Bio, Inc. [MBIO]
Reports for Purchase
Showing records 1 - 20 ( 53 total )
Company: Mustang Bio, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Results; Focused on MB-106 Advancement in WM; Dosing in Phase 2 Expected to Initiate in 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Mustang Bio, Inc.
Industry: Medical - Biomedical and Genetics
MB-106 Moves Into Autoimmune Disease; Financial Lifeline Received; Price Target Reduced to $2
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Mustang Bio, Inc.
Industry: Medical - Biomedical and Genetics
MB-106 Thesis Continues to Strengthen at ASH; Phase 2 WM Trial Set for Mid-2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Mustang Bio, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; Additional MB-106 Phase 1/2 Data at ASH, and More Indications Under the Radar
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Mustang Bio, Inc.
Industry: Medical - Biomedical and Genetics
Initial Phase 1/2 MB-106 Data Show Encouraging Clinical Responses; Further Dose Escalation Expected by YE23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Mustang Bio, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Results; Efforts Concentrated on MB-106 Advancement; Several Data Readouts in 2H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Mustang Bio, Inc.
Industry: Medical - Biomedical and Genetics
MB-106 is On a Roll; High Reponse Rates Impress in Follicular Lymphoma
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Mustang Bio, Inc.
Industry: Medical - Biomedical and Genetics
MB-106''s Antitumor Profile Continues to Mature Following Trial Update at EHA ''23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Mustang Bio, Inc.
Industry: Medical - Biomedical and Genetics
Strategic Regrouping Places Key Emphasis on MB-106; Price Target Adjusted to $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Mustang Bio, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Results; Expecting MB-106 To Shine at EHA
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Mustang Bio, Inc.
Industry: Medical - Biomedical and Genetics
2022 Results; Plentiful Data Readouts and Clinical Updates Expected in the Year to Come
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Mustang Bio, Inc.
Industry: Medical - Biomedical and Genetics
Initial MB-106 Phase 1/2 Data and MB-109 IND Filing At the Top of the List For a Fruitful 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Mustang Bio, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Results; MB-106 Solidifying Starring Role in Pipeline; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Mustang Bio, Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Results; Clinical Programs Raring To Go; Multicenter Phase 1/2 Trial of MB-106 Expected to Start Shortly
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Mustang Bio, Inc.
Industry: Medical - Biomedical and Genetics
First Patient Treated in Europe in Phase 1/2 Study of MB-110 for RAG1-SCID
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Mustang Bio, Inc.
Industry: Medical - Biomedical and Genetics
MB-106''s Efficacy in r/r Follicular Lymphoma Continues to Impress at EHA
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Mustang Bio, Inc.
Industry: Medical - Biomedical and Genetics
Safe and Sound; Updated Phase 1/2 Data Open Doors For MB-107 Pivotal Phase 2 Trial in XSCID
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Mustang Bio, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Results; Data Keep Coming; Key Clinical Updates Continue at EHA for MB-106
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Mustang Bio, Inc.
Industry: Medical - Biomedical and Genetics
MB-106''s Efficacy in Hematologic Malignancies Continues to Impress; Company-Led Phase 1/2 Set to Begin This Quarter
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Mustang Bio, Inc.
Industry: Medical - Biomedical and Genetics
Gene Therapy Conference; We Think Sentiment Starting to Improve
Provider: H.C. Wainwright & Co., Inc.
Analyst: BRANCHETTI E